Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature.
The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which 1 had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of 11 patients with a clinical benefit in 7 (64%) of 11 patients. These results on the use of ET-743 in uterine sarcoma patients support the conductance of larger trials.
Amant
Frédéric
F
Division of Gynecological Oncology, Department of Obstetrics and Gynecology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium. Frederic.amant@uz.kuleuven.ac.be
Coosemans
An
A
Renard
Vincent
V
Everaert
Els
E
Vergote
Ignace
I
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D004149:Dioxoles / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy*; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage*; D000077606:Trabectedin; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy*
D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin